Arena Pharma
Arena’s obesity treatment lorcaserin rejected by FDA
October 25, 2010Sales and Marketing Arena Pharma, Eisai, FDA, FDA complete response letter, lorcaserin, obesity
A new weight loss drug has been rejected by the FDA because of numerous concerns about side-effects and limited efficacy. …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
